Bempedoic acid

Drug Profile

Bempedoic acid

Alternative Names: ESP-55016; ETC-1002

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • Phase II Dyslipidaemias; Hypertension

Most Recent Events

  • 20 Mar 2017 Esperion announces intention to submit NDA to US FDA for Hypercholesterolaemia (Adjunctive treatment) in 1H 2019
  • 03 Feb 2017 Esperion Therapeutics initiates enrolment in the CLEAR Harmony OLE phase III trial for Hypercholesterolaemia in USA (NCT03067441)
  • 01 Jan 2017 Esperion Therapeutics initiates a phase II trial for Hypercholesterolaemia in USA (NCT03051100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top